These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35523287)

  • 1. Correlation between stage of prostate cancer and tyrosine and tryptophan in urine samples measured electrochemically.
    Nasimi H; Madsen JS; Zedan AH; Schmedes AV; Malmendal A; Osther PJS; Alatraktchi FA
    Anal Biochem; 2022 Jul; 649():114698. PubMed ID: 35523287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine and tryptophan in urine as biomarkers for prostate cancer: A validation study.
    Nasimi H; Madsen JS; Zedan AH; Schmedes AV; Malmendal A; Osther PJS; Alatraktchi FA
    J Pharm Biomed Anal; 2024 Nov; 250():116398. PubMed ID: 39121538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score.
    Markin PA; Brito A; Moskaleva N; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; La Frano MR; Appolonova SA
    Metabolomics; 2020 Jun; 16(7):74. PubMed ID: 32556743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of early stage and metastatic prostate cancer using electrochemical detection of beta-2-microglobulin in urine samples from patients.
    Nasimi H; Madsen JS; Zedan AH; Malmendal A; Osther PJS; Alatraktchi FA
    Sci Rep; 2023 Jun; 13(1):10658. PubMed ID: 37391499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.
    Nakayama K; Inoue T; Sekiya S; Terada N; Miyazaki Y; Goto T; Kajihara S; Kawabata S; Iwamoto S; Ikawa K; Oosaga J; Tsuji H; Tanaka K; Ogawa O
    PLoS One; 2014; 9(9):e107234. PubMed ID: 25233230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
    PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplexed quantitative proteomics in prostate cancer biomarker development.
    Gao Y; Kim H; Kitata RB; Lin TT; Swensen AC; Shi T; Liu T
    Adv Cancer Res; 2024; 161():31-69. PubMed ID: 39032952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomics in diagnosis of prostate cancer.
    Davalieva K; Polenakovic M
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer.
    Pichler R; Fritz J; Heidegger I; Steiner E; Culig Z; Klocker H; Fuchs D
    Cancer Sci; 2017 Apr; 108(4):663-670. PubMed ID: 28107600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.
    Johnson H; Guo J; Zhang X; Zhang H; Simoulis A; Wu AHB; Xia T; Li F; Tan W; Johnson A; Dizeyi N; Abrahamsson PA; Kenner L; Feng X; Zou C; Xiao K; Persson JL; Chen L
    BMC Med; 2020 Dec; 18(1):376. PubMed ID: 33256740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of genetic markers in the management of prostate cancer.
    Choudhury AD; Eeles R; Freedland SJ; Isaacs WB; Pomerantz MM; Schalken JA; Tammela TL; Visakorpi T
    Eur Urol; 2012 Oct; 62(4):577-87. PubMed ID: 22695242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
    Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
    Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging biomarkers in the detection and prognosis of prostate cancer.
    Filella X; Foj L
    Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assays for prostate cancer : changing the screening paradigm?
    Hansen J; Rink M; Graefen M; Shariat S; Chun FK
    Mol Diagn Ther; 2013 Feb; 17(1):1-8. PubMed ID: 23355098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New markers in prostate cancer: Genomics.
    Fuessel S; Wirth MP
    Arch Esp Urol; 2019 Mar; 72(2):116-125. PubMed ID: 30855012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers.
    Mengual L; Lozano JJ; Ingelmo-Torres M; Izquierdo L; Musquera M; Ribal MJ; Alcaraz A
    BMC Cancer; 2016 Feb; 16():76. PubMed ID: 26856686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary biomarkers in prostate cancer detection and monitoring progression.
    Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
    Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.